View Item 

Show simple item record

Translational progress on tumor biomarkers
dc.contributor.authorGuo, Hongweien_US
dc.contributor.authorZhou, Xiaolinen_US
dc.contributor.authorLu, Yien_US
dc.contributor.authorXie, Liyeen_US
dc.contributor.authorChen, Qianen_US
dc.contributor.authorKeller, Evan T.en_US
dc.contributor.authorLiu, Qianen_US
dc.contributor.authorZhou, Qinghuaen_US
dc.contributor.authorZhang, Jianen_US
dc.date.accessioned2015-11-12T21:04:16Z
dc.date.available2017-01-03T16:21:17Zen
dc.date.issued2015-11en_US
dc.identifier.citationGuo, Hongwei; Zhou, Xiaolin; Lu, Yi; Xie, Liye; Chen, Qian; Keller, Evan T.; Liu, Qian; Zhou, Qinghua; Zhang, Jian (2015). "Translational progress on tumor biomarkers." Thoracic Cancer (6): 665-671.en_US
dc.identifier.issn1759-7706en_US
dc.identifier.issn1759-7714en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/115962
dc.description.abstractThere is an urgent need to apply basic research achievements to the clinic. In particular, mechanistic studies should be developed by bench researchers, depending upon clinical demands, in order to improve the survival and quality of life of cancer patients. To date, translational medicine has been addressed in cancer biology, particularly in the identification and characterization of novel tumor biomarkers. This review focuses on the recent achievements and clinical application prospects in tumor biomarkers based on translational medicine.en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.othertumor biomarkersen_US
dc.subject.othertranslational medicineen_US
dc.subject.otherTargeted therapyen_US
dc.titleTranslational progress on tumor biomarkersen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelHematology and Oncologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/115962/1/tca12294.pdf
dc.identifier.doi10.1111/1759-7714.12294en_US
dc.identifier.sourceThoracic Canceren_US
dc.identifier.citedreferenceZhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C‐C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102: 522 – 528.en_US
dc.identifier.citedreferenceCai Z, Chen Q, Chen J et al. Monocyte chemotactic protein 1 promotes lung cancer‐induced bone resorptive lesions in vivo. Neoplasia 2009; 11: 228 – 236.en_US
dc.identifier.citedreferenceMahmoud SM, Paish EC, Powe DG et al. Tumor‐infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011; 29: 1949 – 1955.en_US
dc.identifier.citedreferenceWinter C, Kristiansen G, Kersting S et al. Google goes cancer: Improving outcome prediction for cancer patients by network‐based ranking of marker genes. PLoS Comput Biol 2012; 8 ( 5 ): e1002511.en_US
dc.identifier.citedreferenceLee HS, Cho SB, Lee HE et al. Protein expression profiling and molecular classification of gastric cancer by the tissue array method. Clin Cancer Res 2007; 13: 4154 – 4163.en_US
dc.identifier.citedreferenceMoreira F, Kiehl TR, So K et al. NPAS3 demonstrates features of a tumor suppressive role in driving the progression of astrocytomas. Am J Pathol 2011; 179: 462 – 476.en_US
dc.identifier.citedreferenceRoessler S, Jia HL, Budhu A et al. A unique metastasis gene signature enables prediction of tumor relapse in early‐stage hepatocellular carcinoma patients. Cancer Res 2010; 70: 10202 – 10212.en_US
dc.identifier.citedreferenceChan KC. Plasma Epstein‐Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer 2014; 33: 598 – 603.en_US
dc.identifier.citedreferenceMa B, Hui EP, King A et al. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein‐Barr virus DNA as a biomarker of efficacy. Cancer Chemother Pharmacol 2008; 62: 59 – 64.en_US
dc.identifier.citedreferenceGandhi MK, Lambley E, Burrows J et al. Plasma Epstein‐Barr virus (EBV) DNA is a biomarker for EBV‐positive Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 460 – 464.en_US
dc.identifier.citedreferencePeng YH, Xu YW, Huang LS et al. Autoantibody signatures combined with Epstein‐Barr virus capsid antigen‐IgA as a biomarker panel for the detection of nasopharyngeal carcinoma. Cancer Prev Res (Phila) 2015; pii: canprevres.0397.2014. doi: 10.1158/1940‐6207.CAPR‐14‐0397.en_US
dc.identifier.citedreferenceNishino R, Takano A, Oshita H et al. Identification of Epstein‐Barr virus‐induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17: 6272 – 6286.en_US
dc.identifier.citedreferenceZur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2: 342 – 350.en_US
dc.identifier.citedreferenceAgorastos T, Chatzistamatiou K, Katsamagkas T et al. Primary screening for cervical cancer based on high‐risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS ONE 2015; 10 ( 3 ): e0119755.en_US
dc.identifier.citedreferencede Sanjosé S, Ibáñez R, Rodríguez‐Salés V et al. Screening of cervical cancer in Catalonia 2006–2012. Ecancermedicalscience 2015; 9: 532.en_US
dc.identifier.citedreferenceLata K, Bhatla N. HPV testing for cervical cancer screening: Time for a new paradigm. Natl Med J India 2014; 27: 212 – 213.en_US
dc.identifier.citedreferenceCosta S, Venturoli S, Origoni M et al. Performance of HPV DNA testing in the follow‐up after treatment of high‐grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience 2015; 9: 528.en_US
dc.identifier.citedreferenceHäfner N, Driesch C, Gajda M et al. Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts. Oncogene 2008; 27: 1610 – 1617.en_US
dc.identifier.citedreferenceDürst M, Hoyer H, Altgassen C et al. Prognostic value of HPV‐mRNA in sentinel lymph nodes of cervical cancer patients with pN0‐status. Oncotarget 2015. doi: 10.18632/oncotarget.4132.en_US
dc.identifier.citedreferenceIftner T, Becker S, Neis KJ et al. Head‐to‐head comparison of the RNA‐based Aptima® HPV assay and the DNA‐based HC2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol 2015. doi: 10.1128/JCM.01013‐15.en_US
dc.identifier.citedreferenceLanger CJ. Will FLEX allow us flexibility in the therapy of advanced non‐small‐cell lung cancer? Insights from the 2008 American Society of Clinical Oncology Meeting. Clin Lung Cancer 2008; 9: 249 – 251.en_US
dc.identifier.citedreferenceGustafson AM, Soldi R, Anderlind C et al. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med 2010; 2: 26ra25.en_US
dc.identifier.citedreferenceZhang XW, Yan XJ, Zhou ZR et al. Arsenic trioxide controls the fate of the PML‐RARalpha oncoprotein by directly binding PML. Science 2010; 328: 240 – 243.en_US
dc.identifier.citedreferenceCho‐Park PF, Steller H. Proteasome regulation by ADP‐ribosylation. Cell 2013; 153: 614 – 627.en_US
dc.identifier.citedreferenceEmerling BM, Hurov JB, Poulogiannis G et al. Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53‐null tumors. Cell 2013; 155: 844 – 857.en_US
dc.identifier.citedreferenceLeprivier G, Remke M, Rotblat B et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013; 153: 1064 – 1079.en_US
dc.identifier.citedreferenceDong E, Hu H, Hong W. Toward a roadmap from translational medicine to medical practice. Chin Phys Lett 2013; 4: 53 – 62.en_US
dc.identifier.citedreferenceWang J, Wang T, Li YS, Zheng YF, Li LR, Wang Q. Research on constitution of Chinese medicine and implementation of translational medicine. Chin J Integr Med 2015; 32: 389 – 393.en_US
dc.identifier.citedreferenceCesario A, Galetta D, Russo P, Margaritora S, Granone P. The role of the surgeon in translational research. Lancet 2003; 362: 1082.en_US
dc.identifier.citedreferenceKreeger K. From bench to bedside. Nature 2003; 424: 1090 – 1091.en_US
dc.identifier.citedreferenceLedford H. Translational research: The full cycle. Nature 2008; 453: 843 – 845.en_US
dc.identifier.citedreferenceMorrow GR, Bellg AJ. Behavioral science in translational research and cancer control. Cancer 1994; 74: 1409 – 1417.en_US
dc.identifier.citedreferenceSiegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10 – 29.en_US
dc.identifier.citedreferenceSawyers CL. The cancer biomarker problem. Nature 2008; 452: 548 – 552.en_US
dc.identifier.citedreferenceRich N, Singal AG. Hepatocellular carcinoma tumour markers: Current role and expectations. Best Pract Res Clin Gastroenterol 2014; 28: 843 – 853.en_US
dc.identifier.citedreferenceFrazier AL, Hale JP, Rodriguez‐Galindo C et al. Revised risk classification for pediatric extracranial germ cell tumors based on 25 years of clinical trial data from the United Kingdom and United States. J Clin Oncol 2015; 33: 195 – 201.en_US
dc.identifier.citedreferenceSolomon B, Varella‐Garcia M, Camidge DR. ALK gene rearrangements: A new therapeutic target in a molecularly defined subset of non‐small cell lung cancer. J Thorac Oncol 2009; 4: 1450 – 1454.en_US
dc.identifier.citedreferenceGascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913 – 3921.en_US
dc.identifier.citedreferenceStella‐Holowiecka B, Czerw T, Holowiecka‐Goral A, Giebel S, Wojnar J, Holowiecki J. Beta‐2‐microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Transplant Proc 2007; 39: 2893 – 2897.en_US
dc.identifier.citedreferenceDelgado J, Pratt G, Phillips N et al. Beta2‐microglobulin is a better predictor of treatment‐free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009; 145: 801 – 805.en_US
dc.identifier.citedreferenceDeb P, Chakrabarti P, Chakrabarty S et al. Incidence of BCR‐ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate. Indian J Med Paediatr Oncol 2014; 35: 26 – 30.en_US
dc.identifier.citedreferenceFu X, Zhang X. BRAF mutation as a potential marker to identify the proximal colon serrated polyps with malignant potential. Int J Clin Exp Pathol 2014; 7: 7319 – 7322.en_US
dc.identifier.citedreferenceAksenenko MB, Kirichenko AK, Ruksha TG. Russian study of morphological prognostic factors characterization in BRAF‐mutant cutaneous melanoma. Pathol Res Pract 2015; 211: 521 – 527.en_US
dc.identifier.citedreferenceJain P, Cietak KA. Post‐term choriocarcinoma with unusually low beta‐hCG. J Obstet Gynaecol 2008; 28: 661 – 662.en_US
dc.identifier.citedreferenceNolen BM, Lokshin AE. Biomarker testing for ovarian cancer: Clinical utility of multiplex assays. Future Oncol 2013; 17: 139 – 146.en_US
dc.identifier.citedreferenceBanin Hirata BK, Oda JM, Losi Guembarovski R, Ariza CB, de Oliveira CE, Watanabe MA. Molecular markers for breast cancer: Prediction on tumor behavior. Dis Markers 2014; 2014: 513158.en_US
dc.identifier.citedreferenceGeng B, Liang MM, Ye XB, Zhao WY. Association of CA 15‐3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Mol Clin Oncol 2015; 1: 232 – 236.en_US
dc.identifier.citedreferenceMathelin C, Koehl C, Rio MC. Circulating proteinic biomarkers and breast cancer. Gynecol Obstet Fertil 2006; 34: 638 – 646.en_US
dc.identifier.citedreferenceDuffy MJ, McGowan PM, Harbeck N, Thomssen C, Schmitt M. uPA and PAI‐1 as biomarkers in breast cancer: Validated for clinical use in level‐of‐evidence‐1 studies. Breast Cancer Res 2014; 16: 428.en_US
dc.identifier.citedreferenceCalhoun BC, Collins LC. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting. Semin Diagn Pathol 2015; pii: S0740‐2570(15)00012‐X. doi: 10.1053/j.semdp.2015.02.011.en_US
dc.identifier.citedreferenceYamauchi H, Nakagawa C, Yamashige S et al. Societal cost‐effectiveness analysis of the 21‐gene assay in estrogen‐receptor–positive, lymph‐node–negative early‐stage breast cancer in Japan. BMC Health Serv Res 2014; 14: 372.en_US
dc.identifier.citedreferenceDrukker CA, Nijenhuis MV, Bueno‐de‐Mesquita JM et al. Optimized outcome prediction in breast cancer by combining the 70‐gene signature with clinical risk prediction algorithms. Breast Cancer Res Treat 2014; 145: 697 – 705.en_US
dc.identifier.citedreferenceAndicoechea A, Vizoso F, Alexandre E et al. Preoperative carbohydrate antigen 195 (CA195) and CEA serum levels as prognostic factors in patients with colorectal cancer. Int J Biol Markers 1998; 3: 158 – 164.en_US
dc.identifier.citedreferenceReitz D, Gerger A, Seidel J et al. Combination of tumour markers CEA and CA19‐9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol 2015; 68: 427 – 433.en_US
dc.identifier.citedreferenceSun Z, Zhang N. Clinical evaluation of CEA, CA19‐9, CA72‐4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy. World J Surg Oncol 2014; 12: 397.en_US
dc.identifier.citedreferenceBresadola V, Pravisani R, Terrosu G, Risaliti A. Elevated serum CA 19‐9 level associated with a splenic cyst: which is the actual clinical management? Review of the literature. Ann Ital Chir 2015; 86: 22 – 29.en_US
dc.identifier.citedreferenceLiu X, Cai H, Wang Y. Prognostic significance of tumour markers in Chinese patients with gastric cancer. ANZ J Surg 2014; 6: 448 – 453.en_US
dc.identifier.citedreferenceXie M, Huang H, Hang J et al. Evaluation of the analytical and clinical performances of time‐resolved fluoroimmunoassay for detecting carcinoma antigen 50. J Immunoassay Immunochem 2015; 36: 265 – 283.en_US
dc.identifier.citedreferenceTakezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M. [ Tumor markers for pancreatic and biliary tract cancer.] Gan to Kagaku Ryoho 2004; 31: 1443 – 1446. (In Japanese.)en_US
dc.identifier.citedreferenceZhou G, Niu L, Chiu D, He L, Xu K. Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF‐alpha and TSGF after cryosurgery in pancreatic cancer patients. Biotechnol Lett 2012; 34: 1235 – 1241.en_US
dc.identifier.citedreferenceJing JX, Wang Y, Xu XQ et al. Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer. Asian Pac J Cancer Prev 2014; 15: 10267 – 10272.en_US
dc.identifier.citedreferenceGoral V, Yesilbagdan H, Kaplan A, Sit D. Evaluation of CA 72‐4 as a new tumor marker in patients with gastric cancer. Hepatogastroenterology 2007; 54: 1272 – 1275.en_US
dc.identifier.citedreferenceLiu P, Zhu Y, Liu L. Elevated serum CA72‐4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity‐modulated radiation therapy. Oncotarget 2015; 6: 9592 – 9599.en_US
dc.identifier.citedreferenceKwon H, Kim WG, Choi YM et al. A cut‐off value of basal serum calcitonin for detecting macroscopic medullary thyroid carcinoma. Clin Endocrinol 2015; 82: 598 – 603.en_US
dc.identifier.citedreferenceEftekhar E, Naghibalhossaini F. Carcinoembryonic antigen expression level as a predictive factor for response to 5‐fluorouracil in colorectal cancer. Mol Biol Rep 2014; 41: 459 – 466.en_US
dc.identifier.citedreferenceLim SH, Levy R. Translational medicine in action: Anti‐CD20 therapy in lymphoma. J Immunol 2014; 193: 1519 – 1524.en_US
dc.identifier.citedreferenceJensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo‐cecal neuroendocrine tumors. Scand J Gastroenterol 2013; 48: 70 – 77.en_US
dc.identifier.citedreferenceHamada S, Shimosegawa T. Biomarkers of pancreatic cancer. Pancreatology 2011; 11: 14 – 19.en_US
dc.identifier.citedreferenceYasuda M, Saito K, Kobayashi Y et al. Serum carbohydrate antigen elevations in endometrial adenocarcinomas: characterization of DU‐PAN‐2 expression as a tumor marker. J Obstet Gynaecol Res 2004; 30: 59 – 64.en_US
dc.identifier.citedreferenceDoroshow JH. Targeting EGFR in non‐small‐cell lung cancer. N Engl J Med 2005; 353: 200 – 202.en_US
dc.identifier.citedreferencePujol JL, Molinier O, Ebert W et al. CYFRA 21‐1 is a prognostic determinant in non‐small‐cell lung cancer: Results of a meta‐analysis in 2063 patients. Br J Cancer 2004; 90: 2097 – 2105.en_US
dc.identifier.citedreferenceKelly JD, Dudderidge TJ, Wollenschlaeger A et al. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22. PLoS ONE 2012; 7 ( 7 ): e40305.en_US
dc.identifier.citedreferenceCheng L, Bostwick DG, Li G, Zhang S, Vortmeyer AO, Zhuang Z. Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosomes 9p21 and 17p13 in diagnosis. Arch Pathol Lab Med 2001; 125: 1197 – 1199.en_US
dc.identifier.citedreferenceJeong S, Park Y, Cho Y, Kim YR, Kim HS. Diagnostic values of urine CYFRA21‐1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta 2012; 414: 93 – 100.en_US
dc.identifier.citedreferenceXu J, Xu HY, Zhang Q et al. HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 2007; 5: 605 – 614.en_US
dc.identifier.citedreferenceHao Y, Yu Y, Wang L et al. IPO‐38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J Proteome Res 2008; 9: 3668 – 3677.en_US
dc.identifier.citedreferenceKang G, Bae BN, Sohn BS, Pyo JS, Kang GH, Kim KM. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol 2015. doi: 10.1007/s11523‐015‐0361‐1.en_US
dc.identifier.citedreferenceSlipicevic A, Herlyn M. KIT in melanoma: Many shades of gray. J Invest Dermatol 2015; 135: 337 – 338.en_US
dc.identifier.citedreferenceHuang CW, Tsai HL, Chen YT et al. The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer. BMC Cancer 2013; 13: 599.en_US
dc.identifier.citedreferenceBeau‐Faller M, Blons H, Domerg C et al. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non‐small cell lung cancer setting‐IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic national cancer institute platforms. J Mol Diagn 2014; 16: 45 – 55.en_US
dc.identifier.citedreferencevon Eyben FE. A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin Biochem 2001; 34: 441 – 454.en_US
dc.identifier.citedreferenceEpstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 1993; 20: 757 – 770.en_US
dc.identifier.citedreferenceKlatte T, Waldert M, de Martino M, Schatzl G, Mannhalter C, Remzi M. Age‐specific PCA3 score reference values for diagnosis of prostate cancer. World J Urol 2012; 30: 405 – 410.en_US
dc.identifier.citedreferenceKopczyńska E, Kwapisz J, Junik R, Tyrakowski T. Cellular tumor markers in thyroid cancer. Pol Merkur Lekarski 2007; 22: 295 – 299.en_US
dc.identifier.citedreferenceXue G, Liu J, Huang J et al. Detection of galectin‐3 in both serum and tissue for early diagnosis of thyroid carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2013; 33: 1027 – 1030.en_US
dc.identifier.citedreferenceKandoth C, Schultz N, Cherniack AD et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67 – 73.en_US
dc.identifier.citedreferenceNi X, Zhuo M, Su Z et al. Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc Natl Acad Sci U S A 2013; 110: 21083 – 21088.en_US
dc.identifier.citedreferenceKinde I, Bettegowda C, Wang Y et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013; 5: 167ra4.en_US
dc.identifier.citedreferenceWang X, Song X, Zhuo W et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A 2009; 106: 21288 – 21293.en_US
dc.identifier.citedreferenceHarris T, Jimenez L, Kawachi N et al. Low‐level expression of miR‐375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol 2012; 180: 917 – 928.en_US
dc.identifier.citedreferenceRibeiro J, Sousa H. MicroRNAs as biomarkers of cervical cancer development: A literature review on miR‐125b and miR‐34a. Mol Biol Rep 2014; 41: 1525 – 1531.en_US
dc.identifier.citedreferenceKelber JA, Reno T, Kaushal S et al. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res 2012; 72: 2554 – 2564.en_US
dc.identifier.citedreferenceAalaoui‐Jamali M, Bijian K, Batist G. Emerging drug discovery approaches for selective targeting of “precursor” metastatic breast cancer cells: Highlights and perspectives. Am J Transl Res 2011; 3: 434 – 444.en_US
dc.identifier.citedreferenceChen L, Su L, Li J et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre‐warning markers for gastric cancer. Dis Markers 2012; 32: 195 – 202.en_US
dc.identifier.citedreferenceTsai KW, Liao YL, Wu CW et al. Aberrant expression of miR‐196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 2012; 51: 394 – 401.en_US
dc.identifier.citedreferenceBudhu A, Jia HL, Forgues M et al. Identification of metastasis‐related microRNAs in hepatocellular carcinoma. Hepatology 2008; 47: 897 – 907.en_US
dc.identifier.citedreferenceWu L, Qu X. Cancer biomarker detection: Recent achievements and challenges. Chem Soc Rev 2015; 44: 2963 – 2997.en_US
dc.identifier.citedreferenceLu Y, Cai Z, Xiao G et al. Monocyte chemotactic protein‐1 mediates prostate cancer‐induced bone resorption. Cancer Res 2007; 67: 3646 – 3653.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
tca12294.pdf
Size:
97.59KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.